MS
EWTX icon

Maven Securities’s Edgewise Therapeutics EWTX Stock Holding History

Maven Securities’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,300
Closed -$262K – 1137
2021
Q1 		$262K Buy
+8,300
New +$269K 0.01% 846

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Maven Securities's EWTX Position: Q2 2021 in Review

Maven Securities sold out of Edgewise Therapeutics (EWTX) in Q2 2021, closing a stake of 8,300 shares — an estimated $262K sold.

Maven Securities first reported a position in EWTX in Q1 2021 and held it in 1 quarter. The position peaked at $262K in Q1 2021. 46 funds tracked by Wall St. Rank hold EWTX as of Q2 2021.

  • Maven Securities reported no remaining Edgewise Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 8,300 Edgewise Therapeutics shares in Q2 2021, an estimated $262K.
  • Maven Securities first reported a position in Edgewise Therapeutics in Q1 2021 and held it in 1 quarter.
  • Maven Securities's Edgewise Therapeutics position peaked at $262K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.